NeuroInvestment Renamed NeuroPerspective

CARDIFF, CA--(Marketwire - April 27, 2011) -

NI Research is pleased to announce that with the impending publication of the May issue, the name of our flagship monthly publication will be NeuroPerspective. Published since 1995, the name NeuroInvestment has become well known throughout the pharmaceutical industry, but it does not reflect the mission and subscribership that has evolved over the past dozen years, where NI Research’s publications have become the definitive independent reviews of the science and business of neurotherapeutics. Given that our raison d’être is to provide in-depth information accompanied by a distinctive viewpoint, our monthly will now be named what it endeavors to provide: NeuroPerspective.

Harry Tracy PhD, the President of NI Research, noted: “Our readership is now 80% in the biotech/pharma industry, 10% from venture capital and institutional investors, and 10% from consulting firms. It’s time that the name fit the focus.” Recent issues have reviewed R&D programs for schizophrenia, Parkinson’s, and migraine. Upcoming issues will cover insomnia, Alzheimer’s, spinal cord injury, and pain.

NI Research is the leading provider of independent research on the neuropharmaceutical/therapeutic industry. NI Research has published NeuroInvestment since 1995; the Private CNS Company Review since 2003; and CNS Neurotherapeutics/Licensing, an annual compendium of all neuro-oriented R&D programs and pharma licensing agendas/trends, since 2007. NI Research also provides consultation regarding strategic planning and licensing.

NI Research has developed an unmatched information base regarding both publicly and privately held neuro-oriented companies, and offers M&A/licensing consultation and research for large and small pharmaceutical firms.